SpinaFX Triojection® Secures FDA Breakthrough Designation for Innovative Disc Therapy

SpinaFX Medical Inc., a leader in image-guided spinal interventions, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Triojection® system.

This designation underscores the device’s potential to deliver a safer, more effective, and widely accessible treatment option for patients suffering from contained lumbar disc herniations—a major cause of disability worldwide.

The FDA’s Breakthrough Devices Program is designed to accelerate the development and review of innovative medical technologies that offer significant benefits over current therapies for serious or life-threatening conditions. 

This status gives SpinaFX priority engagement with the FDA, fostering a collaborative regulatory pathway and expediting clinical adoption and commercialization.

Triojection® is a minimally invasive, image-guided treatment that utilizes a proprietary oxygen-ozone delivery mechanism to relieve disc pressure and decrease nerve compression. 

Unlike conventional surgery or extended conservative care, this approach provides a targeted outpatient solution that can be delivered in hospitals, ambulatory surgical centers, and clinics, including facilities in resource-limited regions.

The device qualifies for Breakthrough designation as it introduces a new technological advancement in spinal care, addressing contained disc herniations with improved safety, faster recovery, lower costs, and greater accessibility.

Its design and clinical potential position it as a transformative option for patients across a broad range of healthcare environments.